Urothelial Cancer
QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
- Details
ClinicalTrials.gov ID:
NCT04197986
Diagnosis Type:
NA
USOR Number:
- Address
210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889